

# Biotinylated Human CD20 Protein-VLP

Cat. No. CD2-HM122B



## Description

Source	Recombinant Biotinylated Human CD20 Protein-VLP is expressed from HEK293.
	It contains Met1-Pro297.
Accession	P11836-1
Molecular Weight	The target protein has a predicted MW of 34.3 kDa.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by HPLC

## Formulation and Storage


Formulation	Supplied as 0.22µm filtered solution in PBS (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity. CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.


## Assay Data

### SEC-HPLC



The purity of Biotinylated Human CD20 VLP is greater than 95% as determined by SEC-HPLC.

### SPR Data



Biotinylated Human CD20 VLP, captured on CM5 Chip via streptavidin can bind Rituximab, hFc Tag with an affinity constant of 0.68 nM as determined in SPR assay (Biacore T200) (QC Test).


## Biotinylated Human CD20 Protein-VLP

Cat. No. CD2-HM122B



### Assay Data

#### SPR Data



Biotinylated Human CD20 VLP captured on CM5 Chip via streptavidin can bind Ofatumumab, hFc Tag with an affinity constant of 0.61 nM as determined in SPR assay (Biacore T200).